ArticleFrontiers in oncology2021

Cost-Effectiveness Analysis of Fourth- or Further-Line Ripretinib in Advanced Gastrointestinal Stromal Tumors.

Weiting Liao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.